Barclays
INTS icon

Barclays’s Intensity Therapeutics INTS Stock Holding History

Barclays’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$172 Buy
+42
New +$197 ﹤0.01% 5133

Other funds holding INTS

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's INTS Position: Q2 2026 in Review

Barclays opened a new position in Intensity Therapeutics (INTS) in Q2 2026: 42 shares worth $172. The stake represents ﹤0.01% of the portfolio and ranks #5133 among its holdings.

17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Barclays held 42 shares of Intensity Therapeutics worth $172 as of Q2 2026.
  • Intensity Therapeutics was a new Barclays position in Q2 2026.
  • Intensity Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #5133 holding.
  • 17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.